172 related articles for article (PubMed ID: 30302936)
1. Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial.
Collier DJ; Juhasz A; Agabiti-Rosei E; Lloyd E; Hisada M; Zhao L; Kupfer S; Caulfield MJ
J Clin Hypertens (Greenwich); 2018 Oct; 20(10):1473-1484. PubMed ID: 30302936
[TBL] [Abstract][Full Text] [Related]
2. Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.
Neutel JM; Cushman WC; Lloyd E; Barger B; Handley A
J Clin Hypertens (Greenwich); 2017 Sep; 19(9):874-883. PubMed ID: 28681550
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
Sica D; Bakris GL; White WB; Weber MA; Cushman WC; Huang P; Roberts A; Kupfer S
J Clin Hypertens (Greenwich); 2012 May; 14(5):284-92. PubMed ID: 22533654
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.
Ferdinand KC; Bakris GL; Cushman WC; Weber MA; Lloyd E; Wu J; White WB
Am J Cardiol; 2018 Nov; 122(9):1496-1505. PubMed ID: 30217371
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension.
Tsai MC; Wu J; Kupfer S; Vakilynejad M
J Clin Pharmacol; 2016 Aug; 56(8):988-98. PubMed ID: 26632101
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension.
Kipnes MS; Handley A; Lloyd E; Barger B; Roberts A
J Clin Hypertens (Greenwich); 2015 Mar; 17(3):183-92. PubMed ID: 25619410
[TBL] [Abstract][Full Text] [Related]
7. Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review.
Kwon A; Kim GH
Clin Ther; 2020 Jul; 42(7):1390-1403. PubMed ID: 32595000
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
Bakris GL; Sica D; White WB; Cushman WC; Weber MA; Handley A; Song E; Kupfer S
Am J Med; 2012 Dec; 125(12):1229.e1-1229.e10. PubMed ID: 22939358
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
Bakris GL; Zhao L; Kupfer S; Juhasz A; Hisada M; Lloyd E; Oparil S
J Clin Hypertens (Greenwich); 2018 Apr; 20(4):694-702. PubMed ID: 29504252
[TBL] [Abstract][Full Text] [Related]
10. A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension.
Wu J; Du X; Lv Q; Li Z; Zheng Z; Xia Y; Tang C; Yao Z; Zhang J; Long M; Hisada M; Wu J; Zhou W; Ma C
Medicine (Baltimore); 2020 Aug; 99(32):e21465. PubMed ID: 32769878
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone.
Weber MA; Sever P; Juhasz A; Roberts A; Cao C
J Renin Angiotensin Aldosterone Syst; 2018; 19(3):1470320318795000. PubMed ID: 30175930
[TBL] [Abstract][Full Text] [Related]
12. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
Cushman WC; Bakris GL; White WB; Weber MA; Sica D; Roberts A; Lloyd E; Kupfer S
Hypertension; 2012 Aug; 60(2):310-8. PubMed ID: 22710649
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
Sica D; White WB; Weber MA; Bakris GL; Perez A; Cao C; Handley A; Kupfer S
J Clin Hypertens (Greenwich); 2011 Jul; 13(7):467-72. PubMed ID: 21762358
[TBL] [Abstract][Full Text] [Related]
14. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
Bakris GL; Sica D; Weber M; White WB; Roberts A; Perez A; Cao C; Kupfer S
J Clin Hypertens (Greenwich); 2011 Feb; 13(2):81-8. PubMed ID: 21272195
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of azilsartan medoxomil with chlorthalidone in hypertension.
Baker WL; Nigro SC; White WB
Expert Rev Cardiovasc Ther; 2014 Jul; 12(7):791-8. PubMed ID: 24881461
[TBL] [Abstract][Full Text] [Related]
16. Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive.
Pierini D; Anderson KV
Ann Pharmacother; 2013 May; 47(5):694-703. PubMed ID: 23585646
[TBL] [Abstract][Full Text] [Related]
17. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
Cushman WC; Bakris GL; White WB; Weber MA; Sica D; Roberts A; Lloyd E; Kupfer S
J Hypertens; 2018 Apr; 36(4):947-956. PubMed ID: 29334491
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure.
Perez A; Cao C
J Clin Hypertens (Greenwich); 2017 Mar; 19(3):312-321. PubMed ID: 27558280
[TBL] [Abstract][Full Text] [Related]
19. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
Trials; 2015 Dec; 16():581. PubMed ID: 26686682
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.
Bönner G; Bakris GL; Sica D; Weber MA; White WB; Perez A; Cao C; Handley A; Kupfer S
J Hum Hypertens; 2013 Aug; 27(8):479-86. PubMed ID: 23514842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
